Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial

Abstract

At 3 years follow-up, there were no differences in effectiveness between the two strategies, and DES strategy was not more cost-effective as compared to OR plus BMS.